Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxybutynin
Drug ID BADD_D01643
Description Overactive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide. Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life.[A185996,A185999] Oxybutynin, also marketed as Ditropan XL, is an anticholinergic medication used for the relief of overactive bladder symptoms that has been optimized for high levels of safety and efficacy since initial FDA approval in 1975.[A183782,L8648] This drug relieves undesirable urinary symptoms, increasing the quality of life for patients affected by OAB. It is often used as first-line therapy for OAB.[A185990]
Indications and Usage For the treatment of overactive bladder.
Marketing Status Prescription; OTC; Discontinued
ATC Code G04BD04
DrugBank ID DB01062
KEGG ID D00465
MeSH ID C005419
PubChem ID 4634
TTD Drug ID D0R1DH
NDC Product Code 68382-257; 50090-5352; 0615-8220; 70771-1088; 70771-1086; 68382-255; 0023-6153; 71335-0974; 68382-256; 70771-1087; 50090-5353; 0615-8219; 17381-015; 0023-9637
Synonyms oxybutynin | 4-(diethylamino)-2-butynyl-alpha-cyclohexyl-alpha-hydroxybenzeneacetate | 4-(diethylamino)-2-butynyl-alpha-phenylcyclohexaneglycolate | Zatur | Contimin | Cystonorm | Ditropan | Dridase | Cystrin | Dresplan | Driptane | gelnique | Gen-Oxybutynin | Novo-Oxybutynin | Nu-Oxybutyn | Oxyb AbZ | Oxybutin Holsten | Oxybuton | Oxybutynin AL | Oxybutynin AZU | Oxybutynin Heumann | Oxybutynin Hexal | oxybutynin hydrochloride | oxybutynin chloride | Oxybutynin Stada | oxybutynin von ct | Oxybutynin-Puren | Oxybutynin-ratiopharm | Oxymedin | Oxytrol | PMS-Oxybutynin | Pollakisu | Renamel | Ryol | Spasmex Oxybutynin | Spasyt | Tavor | Oxybugamma | Apo-Oxybutynin
Chemical Information
Molecular Formula C22H31NO3
CAS Registry Number 5633-20-5
SMILES CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood pressure increased13.14.03.005--Not Available
Breath odour07.01.06.002--Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Chest discomfort02.02.02.009; 22.02.08.001; 08.01.08.019--Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.011--Not Available
Colitis07.08.01.001--
Confusional state19.13.01.001; 17.02.03.0050.000524%
Congenital central nervous system anomaly17.19.01.003; 03.10.02.0040.000068%Not Available
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.001--
Cough22.02.03.001--
Cycloplegia17.17.02.003; 06.05.03.002--Not Available
Cystitis20.03.02.002; 11.01.14.001--
Death08.04.01.001--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis allergic23.03.04.003; 10.01.03.014--Not Available
Dermatitis atopic23.03.04.016; 10.01.04.004--Not Available
Dermatitis bullous23.03.01.002--
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.0040.000524%
Drug hypersensitivity10.01.01.0010.000917%Not Available
Drug ineffective08.06.01.006--Not Available
Dry eye06.08.02.001--
Dry mouth07.06.01.0020.001048%
Dry skin23.03.03.001--
Dry throat07.06.01.005; 22.02.05.004--Not Available
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 8 Pages